Interim report
Page 1
Biolnvent Q2 INTERIM REPORT JANUARY 1 - JUNE 30 , 2021 CEO Martin Welschof on the new agreement with Merck : " We are very pleased we have reached a second collaboration with MSD ( Merck ) that supports the expansion of the ongoing clinical trial program with our anti - TNFR2 antibody BI - 1808 . We are excited about the potential synergistic activity of BI - 1808 in combination with pembrolizumab and this agreement supports the strong interest elicited by our broadening pipeline of anti - cancer antibodies . " Events in the quarter • Biolnvent received IND approval for Phase 1 / 2a trial of anti - TNFR2 antibody BI - 1808 . ● Biolnvent and Transgene received IND approval from the U.S. FDA for BT - 001 , a novel oncolytic virus delivering an anti - CTLA - 4 antibody for the treatment of solid tumors . ● Biolnvent received notice of allowance in China for the anti - FcyRIIB antibody BI - 1206 patent . Events after the period • ( R ) Biolnvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI - 1808 in combination with Keytruda® ( pembrolizumab ) in patients with advanced solid tumors . Financial information SECOND QUARTER 2021 • Net sales SEK 5.3 ( 15.6 ) million . ● Loss after tax SEK -57.3 ( -39.3 ) million . ● Loss after tax per share before and after dilution SEK -0.98 ( -2.00 ) . ● Cash flow from operating activities and investment activities SEK -65.9 ( -28.4 ) million . JANUARY - JUNE 2021 • Net sales SEK 11.5 ( 32.4 ) million . ● Loss after tax SEK -137.1 ( -72.0 ) million . ● Loss after tax per share before and after dilution SEK -2.75 ( -3.50 ) . ● Cash flow from operating activities and investment activities SEK -117.4 ( -63.9 ) million . • Liquid funds as of June 30 , 2021 : SEK 1,509.7 ( 182.3 ) million . ( R ) = Regulatory event This information is such information as Biolnvent International AB ( publ ) is obliged to make public pursuant to the Securities Markets Act . The information was submitted for publication , through the agency of the contact person set out on page 22 , at 8:00 a.m. CEST on August 26 , 2021 .